Sweet proteins (brazzein, thaumatin, monellin)
01Overview and value chain
Markers: [EC: FDA GRAS notification / “no questions” letter pathway for novel sweet proteins | OECD: Food systems | Regulator: FDA (USA), EFSA (EU)]
Sweet-protein biotech uses precision fermentation to produce intensely sweet, calorie-free proteins — brazzein, thaumatin, monellin and engineered variants — as sugar replacements, moving the category off its historical reliance on plant extraction. Oobli, based in Davis, California, describes itself as the first and only commercial-scale sweet-protein technology platform and received its third FDA “no questions” letter in September 2025 for its brazzein-based sweetening ingredient, following that with an Andean regional manufacturing partnership announced in April 2026 with Magdalena, a sugar producer diversifying into high-value molecules. In Lithuania, Pentasweet broke ground in March 2026 on a €65 million ($76 million) precision fermentation facility in Vilnius — described as Europe’s first commercial-scale sweet-protein factory — with brazzein production expected to begin in the first half of 2027. In Israel, Amai Proteins' engineered sweet protein sweelin received FDA GRAS clearance in February 2026 and Singapore Food Agency approval in May 2026, with clinical trial results published in the journal Food Chemistry confirming blood-glucose safety. And in Finland, the VTT Technical Research Centre engineered Trichoderma reesei fungal strains to express brazzein at approximately 1.3 g/L in bioreactor culture — several-fold higher than prior E. coli or yeast systems — estimating a production cost that could fall to €57–80 per kilogram. Of the catalog’s three named proteins, confirmed live-source activity in this pass concentrates on brazzein; thaumatin’s plant-molecular-farming route is already covered by a sibling article’s Nomad Bioscience entry, and monellin appears in this pass only in general academic reviews of microbial sweet-protein expression, without a confirmed dedicated commercial originator.
The key directions of sweet-protein biotech are:
- Precision-fermented brazzein production (Precision-Fermented Brazzein Production): yeast or fungal hosts engineered to express and secrete brazzein at commercial-scale titers, replacing extraction from the West African oubli fruit.
- Engineered next-generation sweet proteins (Engineered Next-Generation Sweet Proteins): designed protein variants optimized for taste profile and stability beyond any single natural sweet protein.
- Regulatory clearance as a market gate (Regulatory Clearance as a Market Gate): FDA “no questions”/GRAS letters and country-specific food-additive approvals functioning as the primary commercialization bottleneck ahead of scale-up.
- High-titer expression-host engineering (High-Titer Expression-Host Engineering): strain screening and promoter optimization (in Komagataella phaffii, Pichia pastoris, Trichoderma reesei) to raise sweet-protein bioreactor yields and cut production cost.
Sectoral value chain
[expression-host engineering] ──> [fermentation] ──> [protein purification] ──> [regulatory clearance]
│
(taste/stability
validation)
│
▼
[food/beverage formulation & sale] <─── [ingredient formulation] <─────────────────┘Value chain levels
| Level | Description | Key inputs/outputs |
|---|---|---|
| Expression-Host Engineering | engineering a yeast or fungal host strain to express and secrete a sweet protein | In: host organism, sweet-protein gene sequence. Out: engineered production strain. |
| Fermentation | culturing the engineered strain in a bioreactor to produce the sweet protein | In: engineered strain, growth medium. Out: fermentation broth containing sweet protein. |
| Protein Purification | isolating and purifying the sweet protein from the fermentation broth | In: fermentation broth. Out: purified sweet-protein ingredient. |
| Regulatory Clearance | securing FDA no-questions/GRAS status or equivalent food-additive approval | In: purified ingredient, safety/taste data. Out: regulatory clearance for food/beverage use. |
| Ingredient Formulation | blending the cleared sweet protein into a food/beverage sweetening system | In: cleared sweet-protein ingredient. Out: formulated sweetening ingredient. |
| Food/Beverage Formulation & Sale | incorporating the formulated ingredient into a finished consumer product | In: formulated sweetening ingredient. Out: finished low/no-sugar food or beverage. |
Cross-cutting technologies of the sector:
- High-titer strain screening (High-Titer Strain Screening): selection methods (e.g., zeocin-based screening) identifying production clones with elevated sweet-protein yield.
- Fungal/yeast secretion engineering (Fungal/Yeast Secretion Engineering): promoter and expression-system choices (synthetic expression systems, native cbh1 promoter) tuned for extracellular sweet-protein secretion.
- Sweet-protein taste/stability optimization (Sweet-Protein Taste/Stability Optimization): protein engineering targeting off-notes, heat stability and pH tolerance for food and beverage applications.
02US
The US anchors the platform furthest along toward commercial scale, with a regulatory track record spanning multiple clearances and an international manufacturing partnership already announced.
repeated FDA no-questions clearance, brazzein commercialization, Andean manufacturing partnership
- Oobli: describes itself as the first and only commercial-scale sweet-protein technology platform; received its third FDA “no questions” letter in September 2025 for its brazzein-based sweetening ingredient, and announced an Andean regional manufacturing partnership in April 2026 with Magdalena, a sugar producer diversifying into high-value molecules.
03CN
Public information on a dedicated Chinese sweet-protein biotech originator was not confirmed with company-specific detail in this pass; Chinese-language sources describe thaumatin only as a decades-old, plant-extracted commodity food additive (GB 2760, INS 957) rather than a fermentation-based biotech originator.
no confirmed company-specific biotech originator this pass, thaumatin treated as a legacy plant-extracted commodity
- No confirmed company-specific detail this pass: the sources returned for this region were industry market-outlook reports and thaumatin supplier/marketplace listings describing plant-extraction production, not a source confirming a specific Chinese sweet-protein fermentation originator.
04EU
Europe anchors the field’s first commercial-scale fermentation facility, a second commercially cleared engineered sweet protein, and the academic strain-engineering research feeding both.
Europe’s first commercial-scale brazzein factory, a second FDA/Singapore-cleared engineered sweet protein, high-titer fungal strain engineering
- Pentasweet: broke ground in March 2026 on a €65 million ($76 million) precision fermentation facility in Vilnius, Lithuania, described as Europe’s first commercial-scale sweet-protein factory, with brazzein production expected to begin in the first half of 2027.
- Amai Proteins: its engineered sweet protein sweelin received FDA GRAS clearance in February 2026 and Singapore Food Agency approval in May 2026, with clinical trial results published in the journal Food Chemistry confirming blood-glucose safety.
- VTT Technical Research Centre Finland: engineered Trichoderma reesei fungal strains — comparing a synthetic expression system against the native cbh1 promoter — to express brazzein at approximately 1.3 g/L in bioreactor culture, several-fold higher than prior E. coli or yeast systems, with an estimated production cost of €57–80 per kilogram.
05Leading companies and research institutes
| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|---|---|---|---|---|
| Oobli | 🇺🇸 USA | Brazzein sweet-protein platform | 3rd FDA no-questions letter (Sep 2025); Andean manufacturing partnership | Commercial |
| Pentasweet | 🇱🇹 Lithuania | Brazzein precision-fermentation factory | €65M ($76M) Vilnius facility; ops H1 2027 | Commercial |
| Amai Proteins | 🇮🇱 Israel | sweelin engineered sweet protein | FDA GRAS (Feb 2026); Singapore SFA approval (May 2026) | Commercial |
| VTT Technical Research Centre Finland | 🇫🇮 Finland | T. reesei brazzein expression system | ~1.3 g/L bioreactor titer; est. €57–80/kg cost | Research |
06Tech stack and innovations
The stack pairs high-titer expression-host engineering with the regulatory clearance work needed to reach food and beverage shelves.
- High-titer fungal/yeast expression engineering (High-Titer Fungal/Yeast Expression Engineering):
- strain screening and promoter selection raise sweet-protein secretion titers well above earlier bacterial or yeast baselines.
- case: VTT’s synthetic expression system in Trichoderma reesei reached ~1.3 g/L brazzein in bioreactor culture, several-fold above prior E. coli/yeast results, at an estimated €57–80/kg production cost.
- Engineered next-generation sweet-protein design (Engineered Next-Generation Sweet-Protein Design):
- protein engineering beyond a single natural sequence targets improved taste profile, stability and regulatory-ready safety data.
- case: Amai Proteins’ sweelin cleared FDA GRAS and Singapore Food Agency approval, backed by published clinical blood-glucose safety data.
- Regulatory-clearance-gated commercial scale-up (Regulatory-Clearance-Gated Commercial Scale-Up):
- repeated regulatory clearances de-risk investment in dedicated commercial-scale fermentation capacity.
- case: Oobli’s third FDA no-questions letter preceded its Andean manufacturing partnership; Pentasweet’s Vilnius facility represents Europe’s first commercial-scale build-out for the category.
07Value chains and production pipelines
Industrial pipeline of precision-fermented sweet-protein production (FDA GRAS/no-questions framework)
┌───────────────────────────┐ ┌───────────────────────────┐
│ 1. Expression-host eng. │ ───> │ 2. Fermentation │
└───────────────────────────┘ └───────────────────────────┘
│
▼
┌───────────────────────────┐ ┌───────────────────────────┐
│ 4. Regulatory clearance │ <─── │ 3. Protein purification │
└───────────────────────────┘ └───────────────────────────┘
│
▼
┌───────────────────────────┐ ┌───────────────────────────┐
│ 5. Ingredient formulation │ ───> │ 6. Food/beverage sale │
└───────────────────────────┘ └───────────────────────────┘Stage 1: Expression-host engineering
A yeast or fungal host strain is engineered, via promoter selection and strain screening, to express and secrete the target sweet protein at high titer.
Stage 2: Fermentation
The engineered strain is cultured in a bioreactor, producing sweet protein in the fermentation broth.
Stage 3: Protein purification
The sweet protein is isolated and purified from the fermentation broth to food-grade ingredient specification.
Stage 4: Regulatory clearance
The purified ingredient’s safety and taste data support an FDA no-questions/GRAS determination or equivalent food-additive approval elsewhere.
Stage 5: Ingredient formulation
The cleared sweet protein is blended into a sweetening system tuned for a specific food or beverage application.
Stage 6: Food/beverage sale
The formulated ingredient reaches finished consumer products as a calorie-free sugar replacement.
| Supplier | Price | Certificates | Risk | Confidence |
|---|---|---|---|---|
| Oobli | on request | Medium | MEDIUM | |
| Pentasweet | custom | Medium | MEDIUM | |
| Amai Proteins | on request | Medium | MEDIUM | |
| VTT Technical Research Centre Finland | research collaboration | Low | MEDIUM |
AI note: sweet-proteins-brazzein-thaumatin-monellin (EN)
Key directions:
- Precision-fermented brazzein production — yeast/fungal hosts engineered to express brazzein at commercial-scale titers, replacing oubli-fruit extraction.
- Engineered next-generation sweet proteins — designed variants optimized for taste and stability beyond a single natural protein.
- Regulatory clearance as a market gate — FDA no-questions/GRAS letters and country approvals as the primary commercialization bottleneck.
- High-titer expression-host engineering — strain screening and promoter optimization raising bioreactor yields and cutting cost.
Regulatory:
- US/EU: FDA “no questions”/GRAS notification is the operative US pathway (three separate letters for Oobli, one for Amai); EFSA/EU food-additive approval and Singapore’s SFA approval (for Amai) show the multi-jurisdiction clearance burden this category carries before wide retail use.
- China: no dedicated sweet-protein biotech regulator was confirmed this pass — Chinese sources instead cite the GB 2760 national food-additive-use standard (INS 957) under which thaumatin is already listed as a conventional plant-extracted sweetener, predating any fermentation-based clearance question.
Companies not in table: Conagen was investigated as a second US candidate but excluded — its returned sources were generic Komagataella phaffii/Pichia pastoris brazzein-expression academic papers and a research-chemical vendor listing, not company-specific confirmation of a Conagen sweet-protein product. Nomad Bioscience (thaumatin via plant molecular farming) is deliberately NOT repeated here — it already anchors the thaumatin story in the sibling molecular-farming-for-food article, and this article’s own confirmed activity happens to concentrate on brazzein rather than thaumatin, so there was no company-level overlap to resolve, just a topic-level one flagged in the overview prose. China and India were each tried once and returned no company-specific confirmation (China: thaumatin treated purely as a legacy plant-extracted commodity per GB 2760/INS 957 listings; India: no results specific to the region at all, only re-surfaced EU/US sources) — not retried a second time per the cap, per this batch’s convention of accepting a thinner region-count when live sources genuinely don’t confirm a second candidate.
Processing note: this is a cold-start Industry (no INBOX dossier seed) where the catalog title names three specific proteins (brazzein, thaumatin, monellin) but live-source confirmation this pass concentrated almost entirely on brazzein — Oobli, Pentasweet and VTT Finland all work on brazzein specifically, and Amai Proteins’ sweelin is described in sources only as “next-generation sweet protein” without a stated brazzein/thaumatin/monellin lineage, so the article does not assert a mechanism for it beyond what the sources state. This is reported transparently in the Overview rather than papered over — thaumatin’s biotech angle already lives in a sibling article via plant molecular farming (Nomad Bioscience), and monellin appears in this pass only inside a generic India-sourced academic review of microbial sweet-protein expression systems, never tied to a named company. Regions ended up us+eu only (3 of 4 confirmed entities are EU-country-flagged: Lithuania, Israel, Finland) — matching this batch’s established pattern (e.g. enzymatic-therapy-celiac) of tagging only regions with real confirmed activity while still writing all three US/CN/EU H2 sections per the fixed template.
Relevance: this article’s four entries span the full brazzein commercialization curve — from an academic strain-engineering result still reporting yield/cost estimates (VTT Finland, ~1.3 g/L, €57-80/kg) through two different companies’ industrial buildouts (Oobli’s repeated FDA clearances plus an Andean manufacturing deal; Pentasweet’s €65M Vilnius factory, literally Europe’s first of its kind) — plus a fourth company (Amai Proteins) commercializing a differently-branded engineered sweet protein on a parallel regulatory track (FDA GRAS + Singapore SFA + published clinical safety data) rather than brazzein specifically, illustrating that “sweet proteins” as a category is consolidating around brazzein commercially faster than around thaumatin or monellin, at least in this pass’s live sources.